Serial Number:
88494179
Mark:
ALDEYRA
Status:
Registered
Status Date:
09-15-2020
Filing Date:
Registration Number:
6154544
Registration Date:
09-15-2020
Pharmaceutical agents for Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase Inhibition, and by Heat Shock Protein 90 and chaperome Inhibition for the treatment of immune-mediated diseases, dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, Sj�gren-Larsson Syndrome, immune-mediated ocular diseases, systemic diseases, proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer; pharmaceuticals for use in treatment of immune-mediated diseases; pharmaceuticals for use in treating dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sj�gren-Larsson Syndrome; pharmaceuticals for treating immune-mediated ocular diseases and systemic diseases; pharmaceuticals for treating proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer
Mark Description:
The mark consists of the stylized letters and wording "AA ALDEYRA". The letters "AA" appear askew and the second letter "A" is inverted. Centered below the letters "AA" is the word "ALDEYRA".
Class:
Pharmaceutical and veterinary preparations
Type of Mark:
Trademark
Published for Opposition Date:
02-25-2020
Owner:
Mark Drawing Status:
Design plus Words, Letters, and/or Numbers
Abandon Date:
N/A
Business Name:
LANDO & ANASTASI, LLP
Correspondent Name:
